Baxter price target lowered to $77 form $90 at Leerink

Leerink analyst Danielle Antalffy lowered her price target for Baxter to $77 from $90 after the shares sold off in reaction to the company’s first sales miss since Q4 of 2016 and first downward operational sales growth guidance since the mid-2015 split. However, the analyst believes that a Medication Delivery turnaround is achievable with solid execution. Antalffy reiterates an Outperform rating on the shares.
https://thefly.com/landingPageNews.php?id=2815309